• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Quick Take: Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease

byKyle HoffmanandAliya Ramjaun
March 17, 2019
in Chronic Disease, Nephrology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Chronic metabolic acidosis is often seen in patients with chronic kidney disease (CKD), and results from an inability to excrete metabolically produced acid. This, in turn, is associated with bone resorption, muscle catabolism, and progression of kidney disease. Veverimer is a non-absorbable medication that removes hydrochloric acid from the gut lumen in order to combat acidosis. In this multicenter, randomized controlled trial, 217 patients age 18 to 85 years with non-dialysis dependent CKD (estimated glomerular filtration rate between 20 and 40 mL/minute per 1.73 m2) with metabolic acidosis (serum bicarbonate between 12 and 20 mmol/L) were randomly assigned to receive either veverimer or placebo for 12 weeks while adhering to their regular diet to assess the efficacy and safety of veverimer as a treatment for metabolic acidosis in this patient population. Patients were followed up for the composite primary end point, which was the difference in the proportion of patients achieving either a 4 mmol/L increase in serum bicarbonate concentration from baseline or a serum bicarbonate level in the normal range of 22-29 mmol/L. Researchers found that there was a significant increase in the proportion of patients achieving the composite primary endpoint in the veverimer group, as compared to placebo (59% vs. 22%, difference 37%, 95% CI 23% to 49%, p<0.0001). The most common treatment-related adverse events observed in the interventional group were gastrointestinal, including diarrhea, flatulence, nausea, and constipation; these events were typically mild to moderate in severity. This study therefore shows that veverimer is a safe and effective therapy for metabolic acidosis in patients with CKD. Further studies are needed in investigating the long-term effect and safety of this medication.

Click to read the study in Lancet

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

#VisualAbstract: Empagliflozin Has Cardiorenal Benefits for Chronic Kindey Disease

Prevalence of common chronic conditions in Medicare Advantage and traditional Medicare beneficiaries

Denosumab may increase risk of major adverse cardiovascular events but reduce fracture risk in patients receiving dialysis

Tags: chronic kidney disease (CKD)metablic acidosisveverimer
Previous Post

Quick Take: Association of Atopic Dermatitis With Sleep Quality in Children

Next Post

#VisualAbstract: Bag-Mask Ventilation during Tracheal Intubation of Critically Ill Adults

RelatedReports

#VisualAbstract: Empagliflozin Has Cardiorenal Benefits for Chronic Kindey Disease
StudyGraphics

#VisualAbstract: Empagliflozin Has Cardiorenal Benefits for Chronic Kindey Disease

March 6, 2025
Chronic Disease

Prevalence of common chronic conditions in Medicare Advantage and traditional Medicare beneficiaries

February 25, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Chronic Disease

Denosumab may increase risk of major adverse cardiovascular events but reduce fracture risk in patients receiving dialysis

January 13, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Nephrology

Denosumab increases risk of severe hypocalcemia in women with osteoporosis and chronic kidney disease

November 18, 2024
Next Post
#VisualAbstract: Bag-Mask Ventilation during Tracheal Intubation of Critically Ill Adults

#VisualAbstract: Bag-Mask Ventilation during Tracheal Intubation of Critically Ill Adults

Direct oral anticoagulants for atrial fibrillation in patients with mitral stenosis

Direct oral anticoagulants for atrial fibrillation in patients with mitral stenosis

Quick Take: Impact of scribes on emergency medicine doctors’ productivity and patient throughput: multicentre randomised trial

Psychiatric emergency visits increasing among youth, especially racial minorities

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
  • Novel inhibitory antibody, MAR001, lowers triglycerides and remnant cholesterol in humans
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.